The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Cancer cachexia is regulated by selective targeting of skeletal muscle gene products
Open accessAbstract
Cachexia is a syndrome characterized by wasting of skeletal muscle and contributes to nearly one-third of all cancer deaths. Cytokines and tumor factors mediate wasting by suppressing muscle gene products, but exactly which products are targeted by these cachectic factors is not well understood. Because of their functional relevance to muscle architecture, such targets are presumed to represent myofibrillar proteins, but whether these proteins are regulated in a general or a selective manner is also unclear. Here we demonstrate, using in vitro and in vivo models of muscle wasting, that cachectic factors are remarkably selective in targeting myosin heavy chain. In myotubes and mouse muscles, TNF-alpha plus IFN-gamma strongly reduced myosin expression through an RNA-dependent mechanism. Likewise, colon-26 tumors in mice caused the selective reduction of this myofibrillar protein, and this reduction correlated with wasting. Under these conditions, however, loss of myosin was associated with the ubiquitin-dependent proteasome pathway, which suggests that mechanisms used to regulate the expression of muscle proteins may be cachectic factor specific. These results shed new light on cancer cachexia by revealing that wasting does not result from a general downregulation of muscle proteins but rather is highly selective as to which proteins are targeted during the wasting state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2004) · Cell · doi:10.1016/s0092-8674(04)00400-3 · Cited by 3,012
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Self-citationMechanisms of Muscle Wasting — The Role of the Ubiquitin–Proteasome Pathway
Mitch, W. E., & Goldberg, A. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612193352507 · Cited by 1,166
Tisdale, M. J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc927 · Cited by 982
NF-κB-Induced Loss of MyoD Messenger RNA: Possible Role in Muscle Decay and Cachexia
Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C.-Y., & Baldwin Jr., A. S. (2000) · Science · doi:10.1126/science.289.5488.2363 · Cited by 924
Self-citationTumor Necrosis Factor, Other Cytokines and Disease
Tracey, K. J., & Cerami, A. (1993) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.09.110193.001533 · Cited by 783
The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation
Davis, R. L., Cheng, P.-F., Lassar, A. B., & Weintraub, H. (1990) · Cell · doi:10.1016/0092-8674(90)90088-v · Cited by 765 · cited 1×
“This regulation was specific to MyoD, since similar expression of a mutant form of this transcription factor (42) was unable to restore promoter activity.”
BackgroundLecker, S. H., Solomon, V., Mitch, W. E., & Goldberg, A. L. (1999) · The Journal of Nutrition · doi:10.1093/jn/129.1.227s · Cited by 732
Cited by
Evans, W. J., Morley, J. E., Argilés, J., Bales, C., Baracos, V., Guttridge, D., Jatoi, A., Kalantar-Zadeh, K., Lochs, H., Mantovani, G., et al. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2008.06.013 · Cited by 2,450
Self-citationBaracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Self-citationTumors as Organs: Complex Tissues that Interface with the Entire Organism
Egeblad, M., Nakasone, E. S., & Werb, Z. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.05.012 · Cited by 1,234
Tisdale, M. J. (2009) · Physiological Reviews · doi:10.1152/physrev.00016.2008 · Cited by 1,192
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974
Cachexia: pathophysiology and clinical relevance1,2
Morley, J. E., Thomas, D. R., & Wilson, M.-M. G. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.735 · Cited by 786
Skeletal muscle loss: cachexia, sarcopenia, and inactivity
Evans, W. J. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.28608a · Cited by 723
The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683
Mayers, J. R., Wu, C., Clish, C. B., Kraft, P., Torrence, M. E., Fiske, B. P., Yuan, C., Bao, Y., Townsend, M. K., Tworoger, S. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3686 · Cited by 649
Understanding cachexia as a cancer metabolism syndrome
Porporato, P. E. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.3 · Cited by 562
Lenk, K., Schuler, G., & Adams, V. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0007-1 · Cited by 494
Acharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M. L., Carathers, M., Li, Z.-W., Beg, A. A., Ghosh, S., Sahenk, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30556 · Cited by 438
Self-citationCancer cachexia, mechanism and treatment
Aoyagi, T., Terracina, K. P., Raza, A., Matsubara, H., & Takabe, K. (2015) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v7.i4.17 · Cited by 434
Bowen, T. S., Schuler, G., & Adams, V. (2015) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12043 · Cited by 426
Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia
Peixoto da Silva, S., Santos, J. M. O., Costa e Silva, M. P., Gil da Costa, R. M., & Medeiros, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12528 · Cited by 371
NF-κB–mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia
He, W. A., Berardi, E., Cardillo, V. M., Acharyya, S., Aulino, P., Thomas-Ahner, J., Wang, J., Bloomston, M., Muscarella, P., Nau, P., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68523 · Cited by 357
Self-citationBonetto, A., Aydogdu, T., Kunzevitzky, N., Guttridge, D. C., Khuri, S., Koniaris, L. G., & Zimmers, T. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022538 · Cited by 348
“Such declines in muscle mass are known to result from increased protein degradation due to an activation of the proteolytic machinery [32] as well as from loss of specific muscle proteins, such as Myosin Heavy Chain (MyHC) [33].”
BackgroundResultMechanisms of metabolic dysfunction in cancer-associated cachexia
Petruzzelli, M., & Wagner, E. F. (2016) · Genes & Development · doi:10.1101/gad.276733.115 · Cited by 340
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314
Acharyya, S., Butchbach, M. E. R., Sahenk, Z., Wang, H., Saji, M., Carathers, M., Ringel, M. D., Skipworth, R. J. E., Fearon, K. C. H., Hollingsworth, M. A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.004 · Cited by 314
Self-citationBuford, T. W., Anton, S. D., Judge, A. R., Marzetti, E., Wohlgemuth, S. E., Carter, C. S., Leeuwenburgh, C., Pahor, M., & Manini, T. M. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.004 · Cited by 295
Callahan, L. A., & Supinski, G. S. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b6e439 · Cited by 298
Brown, J. L., Rosa‐Caldwell, M. E., Lee, D. E., Blackwell, T. A., Brown, L. A., Perry, R. A., Haynie, W. S., Hardee, J. P., Carson, J. A., Wiggs, M. P., et al. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12232 · Cited by 288
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity
Hanai, J.-I., Cao, P., Tanksale, P., Imamura, S., Koshimizu, E., Zhao, J., Kishi, S., Yamashita, M., Phillips, P. S., Sukhatme, V. P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32741 · Cited by 281
Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3
Fielitz, J., Kim, M.-S., Shelton, J. M., Latif, S., Spencer, J. A., Glass, D. J., Richardson, J. A., Bassel-Duby, R., & Olson, E. N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32827 · Cited by 271
White, J. P., Baynes, J. W., Welle, S. L., Kostek, M. C., Matesic, L. E., Sato, S., & Carson, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024650 · Cited by 260
“In both humans [68,69,70] and rodents cachexia [7,31,71,72,73] induces muscle proteolysis , and the ubiquitin dependent proteasomal system has been reported to be the dominant proteolytic pathway during cachexia [6].”
Wang, H., Hertlein, E., Bakkar, N., Sun, H., Acharyya, S., Wang, J., Carathers, M., Davuluri, R., & Guttridge, D. C. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02020-06 · Cited by 259
Self-citationThe TWEAK–Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice
Mittal, A., Bhatnagar, S., Kumar, A., Lach-Trifilieff, E., Wauters, S., Li, H., Makonchuk, D. Y., Glass, D. J., & Kumar, A. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200909117 · Cited by 250
“Recent evidence suggests that muscle wasting in response to cancer cachexia involves the degradation of only selective muscle proteins (Acharyya et al., 2004, 2005; Acharyya and Guttridge, 2007).”
Stress-induced Skeletal Muscle Gadd45a Expression Reprograms Myonuclei and Causes Muscle Atrophy
Ebert, S. M., Dyle, M. C., Kunkel, S. D., Bullard, S. A., Bongers, K. S., Fox, D. K., Dierdorff, J. M., Foster, E. D., & Adams, C. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.374777 · Cited by 221
Braun, T. P., Zhu, X., Szumowski, M., Scott, G. D., Grossberg, A. J., Levasseur, P. R., Graham, K., Khan, S., Damaraju, S., Colmers, W. F., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111020 · Cited by 213
Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle
Wang, G., Biswas, A. K., Ma, W., Kandpal, M., Coker, C., Grandgenett, P. M., Hollingsworth, M. A., Jain, R., Tanji, K., Lόpez-Pintado, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0054-2 · Cited by 188
Self-citationTurpin, S. M., Lancaster, G. I., Darby, I., Febbraio, M. A., & Watt, M. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00095.2006 · Cited by 164
TNF-α impairs regulation of muscle oxidative phenotype: implications for cachexia?
Remels, A. H. V., Gosker, H. R., Schrauwen, P., Hommelberg, P. P. H., Sliwinski, P., Polkey, M., Galdiz, J., Wouters, E. F. M., Langen, R. C. J., & Schols, A. M. W. J. (2010) · The FASEB Journal · doi:10.1096/fj.09-150714 · Cited by 122
Nutritional interventions for cancer-induced cachexia
Gullett, N. P., Mazurak, V. C., Hebbar, G., & Ziegler, T. R. (2011) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2011.01.001 · Cited by 114
Eley, H. L., Russell, S. T., & Tisdale, M. J. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90530.2008 · Cited by 100
Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo.
Shadfar, S., Couch, M. E., McKinney, K. A., Weinstein, L. J., Yin, X., Rodríguez, J. E., Guttridge, D. C., & Willis, M. (2011) · Nutrition and Cancer · doi:10.1080/01635581.2011.563032 · Cited by 98
“While cancer cachexia is estimated to be the cause of death in more than 20% of all cancer patients, the morbidity and collapse in the quality of life affects nearly all patients (2,4,5).”
BackgroundInfluentialSmad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice
Winbanks, C. E., Murphy, K. T., Bernardo, B. C., Qian, H., Liu, Y., Sepulveda, P. V., Beyer, C., Hagg, A., Thomson, R. E., Chen, J. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4976 · Cited by 95
Englund, D. A., Zhang, X., Aversa, Z., & LeBrasseur, N. K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111595 · Cited by 94
Mitochondrial dynamics in cancer-induced cachexia
van der Ende, M., Grefte, S., Plas, R., Meijerink, J., Witkamp, R. F., Keijer, J., & van Norren, K. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.008 · Cited by 87
You, J.-S., Park, M.-N., Song, W., & Lee, Y.-S. (2010) · Applied Physiology Nutrition and Metabolism · doi:10.1139/h10-022 · Cited by 88
Hall, D. T., Griss, T., Ma, J. F., Sanchez, B. J., Sadek, J., Tremblay, A. M. K., Mubaid, S., Omer, A., Ford, R. J., Bedard, N., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708307 · Cited by 88
“In keeping with this, induction of muscle atrophy can be recapitulated in culture and in vivo by exposure to different cytokine combinations [e.g., IFNc and TNFa (Guttridge et al, 2000; Acharyya et al, 2004; Di Marco et al, 2005, 2012) or IL-6 (Bonetto et al, 2012; White et al, 2012)].”
Background(2008) · PubMed · Cited by 84
Anti-TNF Treatment Reduces Rat Skeletal Muscle Wasting in Monocrotaline-Induced Cardiac Cachexia
Steffen, B. T., Lees, S. J., & Booth, F. W. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.90884.2008 · Cited by 81
(2019) · doi:10.1371/journal.pbio.3000434 · Cited by 79
Loss of appetite in acutely ill medical inpatients: physiological response or therapeutic target?
Schütz, P., Bally, M., Stanga, Z., & Keller, U. (2014) · Swiss Medical Weekly · doi:10.4414/smw.2014.13957 · Cited by 78
PERK regulates skeletal muscle mass and contractile function in adult mice
Gallot, Y. S., Bohnert, K. R., Straughn, A. R., Xiong, G., Hindi, S. M., & Kumar, A. (2019) · The FASEB Journal · doi:10.1096/fj.201800683rr · Cited by 67
Bohnert, K. R., Goli, P., Roy, A., Sharma, A. K., Xiong, G., Gallot, Y. S., & Kumar, A. (2019) · Molecular and Cellular Biology · doi:10.1128/mcb.00184-19 · Cited by 52
Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions
Wang, T., Zhou, D., & Hong, Z. (2025) · MedComm · doi:10.1002/mco2.70030 · Cited by 46
Lee, H., Lim, J.-Y., & Choi, S.-J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2739721 · Cited by 43
Kaur, N., Gupta, P., Saini, V., Sherawat, S., Gupta, S., Dua, A., Kumar, V., Injeti, E., & Mittal, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27348 · Cited by 40
“About one‐third of all cancer patients die from direct consequences of cachexia (Acharyya et al., 2004).”
BackgroundDietary Intake of Probiotic Kimchi Ameliorated Il-6-Driven Cancer Cachexia
An, J. M., Kang, E. A., Han, Y.-M., Oh, J. Y., Lee, D. Y., Choi, S. H., Kim, D. H., & Hahm, K. B. (2019) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.19-10 · Cited by 33
Sharma, B., Dutt, V., Kaur, N., Mittal, A., & Dabur, R. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112720 · Cited by 34
S-Allyl Cysteine: A Potential Compound against Skeletal Muscle Atrophy
Gupta, P., Dutt, V., Kaur, N., Kalra, P., Gupta, S., Dua, A., Dabur, R., Saini, V., & Mittal, A. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129676 · Cited by 25
You, J.-S., Park, M.-N., & Lee, Y.-S. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.07.007 · Cited by 24
Metadata
- Authors
- Acharyya, S., Ladner, K. J., Nelsen, L. L., Damrauer, J., Reiser, P. J., Swoap, S., & Guttridge, D. C.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-08-01
- Volume
- 114
- Issue
- 3
- Pages
- 370-378
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2122248675
- Cited by
- 542
- References
- 62
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.